文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

放疗后前列腺癌局部复发的挽救性立体定向体部放疗:GETUG多中心回顾性研究

Salvage Stereotactic Body Radiation Therapy for Local Prostate Cancer Recurrence After Radiation Therapy: A Retrospective Multicenter Study of the GETUG.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2019-07-22

该多中心回顾性研究纳入100例经活检证实放疗后局部复发的前列腺癌患者,评估挽救性SBRT的疗效与安全性。中位随访29.3个月,3年生化无复发生存率为55%,3级及以上泌尿生殖毒性发生率低,但3年≥2级泌尿生殖毒性为20.8%。

要点

  • 挽救性SBRT后3年生化无复发生存率为55%(95%CI 42%-66%)。
  • 3年≥2级泌尿生殖毒性和胃肠毒性分别为20.8%和1%。
  • 初始D'Amico分组、首程放疗间隔时间和SBRT剂量是生化无复发生存的预后因素。

核心结论

  • 挽救性SBRT可获得令人鼓舞的肿瘤控制且毒性可接受,但随访时间短,需前瞻性研究确认并评估晚期毒性。

研究设计与样本

  • 多中心回顾性研究,2010年4月至2017年1月纳入7个中心的100例经活检证实放疗后局部复发的前列腺癌患者。

主要发现

  • 中位随访29.3个月(范围4-91),3年生化无复发生存率为55%(95%CI 42%-66%)。
  • 无患者发生>1级急性胃肠毒性,2级和3级急性泌尿生殖毒性发生率分别为8%和1%。
  • 3年≥2级泌尿生殖和胃肠毒性的实际发生率分别为20.8%(95%CI 13%-29%)和1%(95%CI 0.1%-5.1%)。
  • 1例患者出现3级神经炎。

关键数值与推荐

  • 中位SBRT剂量为36 Gy(范围25-36.25 Gy),分6次(范围5-6次),隔日照射。
  • 复发时中位前列腺特异性抗原为4.3 ng/mL(范围2-38),两次治疗中位间隔7.5年(范围2-18)。
  • 87%和94%的患者分别接受盆腔多参数磁共振成像和胆碱正电子发射断层扫描评估疾病范围。
  • 毒性按照常见不良事件评价标准4.03版评估。

临床怎么用

  • 对于放疗后经活检证实的局部前列腺癌复发,挽救性SBRT可作为一种控制率较好且毒性可接受的选项。
  • 治疗前应完善盆腔多参数磁共振成像和胆碱正电子发射断层扫描以评估疾病范围。
  • 需关注泌尿生殖毒性,尤其是≥2级毒性,并长期随访评估晚期毒性。

局限性

  • 回顾性研究设计。
  • 随访时间较短(中位29.3个月),晚期毒性尚未充分评估。
  • 样本量有限(100例),结果需前瞻性研究进一步确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To assess the efficacy and safety of salvage stereotactic body radiation therapy (SBRT) in patients with biopsy-proven local prostate cancer recurrence after radiation therapy. METHODS AND MATERIALS: Between April 2010 and January 2017, 100 patients were included in 7 centers. Disease extension was assessed by pelvic multiparametric magnetic resonance imaging and choline positron emission tomography in 87% and 94% of patients, respectively. The median time interval between the 2 treatments was 7.5 years (range, 2-18). Median prostate-specific antigen at recurrence was 4.3 ng/mL (range, 2-38). Median SBRT dose was 36 Gy (range, 25-36.25) in 6 fractions (range, 5-6), every other day. Thirty-four percent of patients were treated by androgen deprivation therapy for a median duration of 12 months. Toxicity was assessed according to Common Terminology Criteria for Adverse Events version 4.03. RESULTS: Median follow-up was 29.3 months (range, 4-91). Second biochemical recurrence-free survival rate at 3 years was 55% (95% confidence interval [CI], 42%-66%). The initial D'Amico group, time interval after first radiation therapy, and SBRT dose were prognostic factors of biochemical recurrence-free survival in multivariate analysis (P = .09, P = .025, P = .018, respectively). No patient developed acute gastrointestinal toxicity of grade >1; rates of acute genitourinary toxicity of grade 2 and 3 were 8% and 1%, respectively. The actuarial 3-year grade ≥2 genitourinary and gastrointestinal toxicity was 20.8% (95% CI, 13%-29%) and 1% (95% CI, 0.1%-5.1%), respectively. One patient presented with neuritis of grade 3. CONCLUSIONS: With a short follow-up, this study shows that salvage SBRT allows for encouraging control and acceptable toxicity. Further prospective studies are necessary to confirm these preliminary results and to determine late toxicity.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Pasquier D, Martinage G, Janoray G, et al. Salvage Stereotactic Body Radiation Therapy for Local Prostate Cancer Recurrence After Radiation Therapy: A Retrospective Multicenter Study of the GETUG. Int J Radiat Oncol Biol Phys. 2019. PMID: 31344433. doi:10.1016/j.ijrobp.2019.07.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。